Funds will help advance MDS Education, Advocacy
and Research
SAN
DIEGO, Dec. 13, 2023 /PRNewswire/ -- Notable
Labs, Ltd. ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic
platform company developing predictive precision medicines for
cancer patients, today announced that it has donated
$60,000 to the Myelodysplastic
Syndromes Foundation, Inc. This donation was formally announced
during the MDS Foundation 2023 Satellite Symposium at the 65th
American Society of Hematology (ASH) Annual Meeting in San Diego, which was also supported by
Notable.
"This funding reflects our deep commitment to developing better
treatments for patients with MDS who deserve the fastest possible
progress in fighting this severe, life-threatening disease," said
Thomas Bock, MD, CEO, Notable
Labs. "I am truly excited about partnering with the MDS
Foundation in fighting this severe and life-threatening condition.
Notable is focused on improving the lives of patients with the most
pressing medical needs through novel treatment paradigms.
Collaborating with the patient and medical communities is at the
core of our mission."
Notable Labs served as a National Gold Sponsor of the 2023
Move for MDS Community Walks to Drive Awareness & Accelerate
Research and participated in MDS Community Walks which occurred
in Chicago, New York City, Los
Angeles, Nashville, and
Boston. The Move's virtual walk is
still ongoing and can be joined here.
"We are extremely grateful to Notable Labs for their generous
sponsorship of our 2023 Move for MDS Community Walks," said
Tracey Iraca, Executive Director,
MDS Foundation. "The funds raised by the MDS Foundation are
used to educate patients and caregivers, as well as to raise
awareness of MDS in the community. We also work tirelessly to
educate healthcare providers and support innovative research in the
fields of MDS and its related continuum of diseases to better
diagnose, control and ultimately cure these diseases."
For more information about Move for MDS, please visit:
https://moveformds.org/#about-mds.
About Notable Labs
Notable Labs, Ltd. is a
clinical-stage platform therapeutics company developing predictive
precision medicines for patients with cancer. Through its
proprietary Predictive Precision Medicines Platform (PPMP), Notable
Labs bio-simulates a cancer treatment and aims to predict whether
or not a patient is likely to respond to that specific therapeutic.
Notable Labs' PPMP is designed to identify and select clinically
responsive patients prior to their treatment and thus fast-track
clinical development in this patient population. By continually
advancing and expanding the reach of the PPMP across diseases and
predicted medical outcomes, Notable Labs aims to be the leader in
precision medicine and revolutionize the way in which patients seek
and receive treatments that work best for them – patient by patient
and cancer by cancer. Notable Labs believes it has created a
targeted and de-risked in-licensing strategy to deliver a product's
medical impact and commercial value faster, higher, and with a
greater likelihood of success than traditional drug development. By
transforming historical standards of care, Notable Labs aims to
create dramatic positive impact for patients and the healthcare
community. Notable Labs is headquartered in Foster City, California. Learn more at
www.NotableLabs.com and follow us @NotableLabs.
About the MDS Foundation, Inc.
The MDS Foundation has
been at the forefront of providing comprehensive support and
education for the MDS community for nearly 30 years. With a vision
to ensure that every MDS patient benefits from early initiatives
and research, the foundation focuses on better diagnosis, control,
and ultimately, the cure of MDS and its related diseases. As part
of their ongoing commitment to the MDS patient population, the
foundation has initiated a project to raise awareness about
clinical trials, streamline the search process, and facilitate
patient-care team interactions. For more information and to access
the new portal, visit www.mds-foundation.org.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including but not limited to, express or implied statements
regarding Notable's future operations and goals; the potential
benefits of any therapeutic candidates or platform technologies of
Notable; the timing of any clinical milestones of Notable's
therapeutic candidates; the cash runway of the combined company;
and other statements that are not historical fact. All statements
other than statements of historical fact contained in this
communication are forward-looking statements. These forward-looking
statements are made as of the date they were first issued, and were
based on the then-current expectations, estimates, forecasts, and
projections, as well as the beliefs and assumptions of management.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which involve factors or circumstances that
are beyond Notable's control. Notable's actual results could differ
materially from those stated or implied in forward-looking
statements due to a number of factors, including but not limited to
(i) uncertainties associated with Notable's platform technologies,
as well as risks associated with the clinical development and
regulatory approval of product candidates, including potential
delays in the commencement, enrollment and completion of clinical
trials; (ii) risks related to the inability of Notable to obtain
sufficient additional capital to continue to advance these product
candidates and any preclinical programs; (iii) uncertainties in
obtaining successful clinical results for product candidates and
unexpected costs that may result therefrom; (iv) risks related to
the failure to realize any value from product candidates and
preclinical programs being developed and anticipated to be
developed in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; (v) risks
associated with Notable's future financial and operating results,
including its ability to become profitable; (vi) Notable's ability
to retain key personnel; (vii) Notable's ability to manage the
requirements of being a public company; (viii) uncertainties
relating to the Israel-Hamas war; (ix) Notable's ability to obtain
orphan drug designation, and the associated benefits, for any of
its drug candidates; (x) Notable's inability to obtain regulatory
approval for any of its drug candidates; and (xi) changes in, or
additions, to international, federal, state or local legislative
requirements, such as changes in or additions to tax laws or rates,
pharmaceutical regulations, and other regulations. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties. These and other risks and uncertainties
are more fully described in periodic filings with the U.S.
Securities and Exchange Commission ("SEC"), including the factors
described in the section titled "Risk Factors" in the Registration
Statement of Vascular Biogenics Ltd. on Form S-4, as filed with the
SEC on September 1, 2023, the
Quarterly Report on Form 10-Q of Notable Labs, Ltd. as filed with
the SEC on November 14, 2023, and in
other subsequent filings with the SEC. You should not place undue
reliance on these forward-looking statements, which are made only
as of the date hereof or as of the dates indicated in the
forward-looking statements. Notable expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statements are based.
Media contacts:
John F. Kouten
JFK Communications, Inc.
908-227-4714
jfkouten@jfkhealth.com
Tracey Iraca, Executive
Director
MDS Foundation, Inc.
tiraca@mds-foundation.org
609-298-1600 x211
View original content to download
multimedia:https://www.prnewswire.com/news-releases/notable-labs-donates-60-000-to-mds-foundation-to-accelerate-progress-for-patients-with-myelodysplastic-syndromes-302014331.html
SOURCE Notable Labs